Skip to main content

Table 1 Clinicopathological features of the ESCC patients enrolled in this retrospective study

From: SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

Characteristic, n (%) pCR non-pCR P
pT0N0 pT0N1-3 pT1-4N0 pT1-4N1-3
n=25 n=10 n=40 n=40
Median age (range) 63 (44–77) 65 (53–75) 66 (43–74) 63 (41–75) 0.2402
Gender      0.7178
Female 5 (20.0) 1 (10.0) 8 (20.0) 5 (12.5)  
Male 20 (80.0) 9 (90.0) 32 (80.0) 35 (87.5)  
Tumor location      0.8228
Upper 5 (20.0) 2 (20.0) 8 (20.0) 9 (22.5)  
Middle 9 (36.0) 4 (40.0) 18 (45.0) 21 (52.5)  
Lower 11 (44.0) 4 (40.0) 14 (35.0) 10 (25.0)  
Tumor differentiation      0.5425
Not poorly 20 (80.0) 8 (80.0) 36 (90.0) 36 (90.0)  
Poorly 5 (20.0) 2 (20.0) 4 (10.0) 4 (10.0)  
Depth of invasion (cT)      0.0567
T1-2 5 (20.0) 3 (30.0) 2 (5.0) 3 (7.5)  
T3-4 20 (80.0) 7 (70.0) 38 (95.0) 37 (92.5)  
Lymph node metastasis (cN)      0.5858
N1 18 (72.0) 8 (80.0) 26 (65.0) 24 (60.0)  
N2-3 7 (28.0) 2 (20.0) 14 (35.0) 16 (40.0)  
Distant metastasis (cM)      0.2138
M0 19 (76.0) 10 (100) 36 (90.0) 35 (87.5)  
M1 (lymph node) 6 (24.0) 0 (0) 4 (10.0) 5 (12.5)  
Clinical stage(cStage)      0.1051
I 1 (4.0) 1 (10.0) 2 (5.0) 0 (0)  
II 3 (12.0) 2 (20.0) 0 (0) 3 (7.5)  
III 14 (56.0) 6 (60.0) 34 (85.0) 31 (77.5)  
IVA 1 (4.0) 1 (10.0) 0 (0) 1 (2.5)  
IVB 6 (24.0) 0 (0) 4 (10.0) 5 (12.5)  
Recurrence      0.0456a
Presence 5 (20.0) 4 (40.0) 15 (37.5) 22 (55.0)  
Absence 20 (80.0) 6 (60.0) 25 (62.5) 18 (45.0)  
Prognosis      0.3115
Alive 22 (88.0) 6 (60.0) 27 (67.5) 24 (60.0)  
Dead with ESCC 2 (8.0) 3 (30.0) 10 (25.0) 14 (35.0)  
Dead with other diseases 1 (4.0) 1 (10.0) 3 (7.5) 2 (5.0)  
  1. pCR pathological complete response, ESCC esophageal squamous cell carcinoma
  2. *Statistically significant